Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: A randomized assessor-blind controlled trial

Human Reproduction

Volumn 21, Issue 12, 2006, Pages 3217-3227

  Andersen, Anders Nyboe ^a   Devroey, Paul ^b   Arce, Joan Carles ^c  

^a Rigshospitalet   (Denmark)

^b CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^c Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Embryo quality; Highly purified menotrophin; IVF; Pregnancy; Recombinant FSH

Indexed keywords

ESTRADIOL; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ABDOMINAL DISTENSION; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED HEADACHE; EMBRYO TRANSFER; ENDOMETRIUM; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OVARY FOLLICLE DEVELOPMENT; OVARY HYPERSTIMULATION; PELVIS PAIN SYNDROME; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 33751377584     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del284     Document Type: Article

References (23)

1. Arce J-C, Nyboe Andersen A and Collins J (2005) Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: A mini-review. Hum Reprod 20,1757-1771.
2. Assou S, Anahory T, Pantesco V, Le Carrour T, Pellestor F, Klein B, Reyftmann L, Dechaud H, De Vos J and Hamamah S (2006) The human cumulus-oocyte complex gene-expression profile. Hum Reprod 21(7),1705-1719.
3. European Medicines Agency (2005) Guideline on the choice of the non-inferiority margin. EMEA/CPMP/EWP/2158/99.
4. European Medicines Agency (2000) Points to consider on switching between superiority and non-inferiority. CPMP/EWP/482/99.
5. Daya S (2003) Pitfalls in the design and analysis of efficacy trials in subfertility. Hum Reprod 18,1005-1009.
6. ESHRE (2006) The European IVF-monitoring programme (EIM) for the European Society for Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2002. Results generated from European registers by ESHRE. Hum Reprod 21(7),1680-1697.
7. European Medicines Agency (1998). ICH Topic E9. Note for guidance on statistical principles for clinical trials. CPMP/ICH/363/96.
8. European Medicines Agency (2001). ICH Topic E10. Note for guidance on choice of control group in clinical trials. CPMP/ICH/364/96.
9. The European and Israeli Study Group on highly purified hMG versus rFSH (2002) Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/ intracytoplasmic sperm injection cycles: A randomized, comparative trial. Fertil Steril 78,520-528.
10. Fanchin R, Righini C, Olivennes F, Taieb J, De Ziegler D and Frydman R (1999) Computerized assessment of endometrial echogenicity: Clues to the endometrial effects of premature progesterone elevation. Fertil Steril 71,174-181.
11. Fanchin R, Righini C, Ayoubi J-M, Olivennes F, de Ziegler D and Frydman R (2000) New look at endometrial echogenicity: Objective computer-assisted measurements predict endometrial receptivity in in vitro fertilization-embryo transfer. Fertil Steril 74,274-281.
12. Filicori M and Cognigni GE (2001) Roles and novel regimens of luteinizing hormone and follicle-stimulating hormone in ovulation induction. J Clin Endocrinol Metab 86,1437-1441.
13. Filicori M, Cognigni GE, Pocognoli P, Tabarelli C, Spettoli D, Taraborrelli S and Ciampaglia W (2002) Modulation of folliculogenesis and steroidogenesis in women by graded menotropin administration. Hum Reprod 17,2009-2015.
14. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z and Caspi E (1989) Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv 44,430-440.
15. Helmgaard L, Sorensen P and Arce J-C (2004) Children born after controlled ovarian stimulation with HP-hMG or recombinant FSH: Results of the EISG pregnancy outcome follow-up. Fertil Steril 82(Suppl 2),S232.
16. Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R and Campbell A (2005) Evaluation of two doses of recombinant luteinising hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril 83,309-315.
17. Platteau P, Smitz J, Albano C, Sørensen P, Arce J-C and Devroey P (2004) Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertil Steril 81,1401-1404.
18. Platteau P, Nyboe Andersen A, Balen A, Devroey P, Sorensen P, Helmgaard L and Arce J-C (2006) Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO group II anovulatory infertility: A randomized controlled study. Hum Reprod 21(7),1798-1804.
19. Vail A and Gardener E (2003) Common statistical errors in the design and analysis of subfertility trials. Hum Reprod 18,1000-1004.
20. van Wely M, Westergaard LG, Bossuyt PMM and Van der Veen F (2003) Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles (Cochrane review). The Cochrane Library, Issue 1. Update Software, Oxford.
21. Westergaard LG, Erb K, Laursen SB, Rex S and Rasmussen PE (2001) Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotrophic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: A prospective randomized study. Fertil Steril 76,543-549.
22. Weston AM, Zelinski-Wooten MB, Hutchinson JS, Stouffer RL and Wolf DP (1996) Developmental potential of embryos produced by in-vitro fertilization from gonadotrophin-releasing hormone antagonist-treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinising hormone. Hum Reprod 11,608-613.
23. Wolfenson C, Groisman J, Couto AS, Hedenfalk M, Cortvrindt RG, Smitz JEJ and Jespersen S (2005) Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online 10,442-454.